Bafna Pharmaceuticals Limited — Board Meeting, 26-05-2025: Outcome of Board Meeting

Bafna Pharmaceuticals has announced a board meeting on which it approved the audited financial results for the quarter and year ended March 31, 2025. The company posted total income of ₹148.6 Cr and a profit before tax of ₹41.5 Cr, despite exceptional write-offs on inventory and intangible assets. Operational cash flow remained solid at ₹22.1 Cr. Meanwhile, the Madhavaram manufacturing unit’s assets are classified as held for sale, with the sale process underway. Key audit appointments were made for internal, secretarial, and cost audit functions through FY26.